DrugPatentWatch Database Preview
Biologic Drugs With Dosage Form: INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER
» See Plans and Pricing
Details for Dosage Type: INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER | 125526 | 001 | 2015-11-04 | Start Trial | Aegis Therapeutics LLC (San Diego, CA) | 2026-06-23 | RX | Orphan | search |
Glaxosmithkline Llc | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER | 125526 | 001 | 2015-11-04 | Start Trial | Atopix Therapeutics Limited (Abingdon, Oxon, GB) | 2031-03-07 | RX | Orphan | search |
Glaxosmithkline Llc | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER | 125526 | 001 | 2015-11-04 | Start Trial | Aegis Therapeutics, LLC (San Diego, CA) | 2026-06-23 | RX | Orphan | search |
Glaxosmithkline Llc | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER | 125526 | 001 | 2015-11-04 | Start Trial | Array BioPharma, Inc. (Boulder, CO) Genentech, Inc. (South San Francisco, CA) | 2027-07-05 | RX | Orphan | search |
Glaxosmithkline Llc | NUCALA | mepolizumab | INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER | 125526 | 001 | 2015-11-04 | Start Trial | City of Hope (Duarte, CA) | 2030-10-08 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |